Nanotechnology Now - Press Release: eFoodSafety Introduces Patented Nano-Encapsulation Technology to Its Products

Home > Press > eFoodSafety Introduces Patented Nano-Encapsulation Technology to Its Products

Abstract:
Nano-Encapsulation Allows for Maximum Cellular Absorption of Treatments by the Body and Enhanced Efficiency of Drug Delivery

eFoodSafety Introduces Patented Nano-Encapsulation Technology to Its Products

Scottsdale, AZ | Posted on January 16th, 2008

eFoodSafety.com, Inc. (OTCBB:EFSF, http://www.efoodsafety.com) has developed a novel patented technology that has the ability to nano-encapsulate active ingredients in nutraceutical and cosmeceutical products and utilizes a unique food grade compound. This means that the nano-capsules break down and are absorbed as common foods after they have delivered their active ingredients. Cellular absorption of nutrients is maximized while toxicity is minimized. Using this technology, eFoodSafety can encapsulate a multitude of bioactive and active ingredients within any given formula.

The Freedonia Group recently projected world demand for nano-materials to reach $4.2 billion by 2011 and $100 billion by 2025, with widespread use in drug delivery applications as a significant growth factor.

"By introducing nanotechnology to our products, we are broadening our opportunities to treat common health conditions that affect millions of people worldwide," comments Patricia Gruden, CEO of eFoodSafety. "In addition to our strong product portfolio and promising clinical results, we believe we now have a superior and novel method to dramatically improve delivery of these ingredients. We expect that this advance will have a positive impact on our products."

####

About eFoodSafety.com, Inc.
eFoodSafety.com, Inc., based in Scottsdale, Arizona, is dedicated to improving health conditions around the world through its innovative technologies. The company’s Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin™ (formerly named Big Six Plus) – EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The OraPhyte™ product, which has been tested and shown to be effective at eradicating nematodes by the U.S. Department of Agriculture, is currently at three major universities with outstanding Agricultural Departments undergoing crop-specific research.

The company’s Cinnergen™ is a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism, is available for sale at (www.cinnergen.com) and through national retailers; its Cinnechol™ is a multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect™ anti-acne skin care system.

The company’s iBoost, Inc. subsidiary is the distributor of the Immune Boost Bar™, a non-dairy, no refined sugar, all-natural and comprehensive multi-nutrient product that helps fortify the body’s immune system. The product contains Citroxin™, eFoodSafety’s proprietary all natural supplement proven effective in fighting several types of harmful bacteria, and forty active compounds that assist with enhancing immunity, detoxification, cleansing, and metabolic efficiency. The Immune Boost Bar™ is available in three delicious flavors: chocolate, oatmeal-raisin, mint and peanut butter and can be purchased at www.immuneboost.com.

The company’s MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the owner of the Talsyn™-CI/bid Scar Cream, a product that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn™ line.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are “forward-looking statements.” Such forward-looking statements are sometimes identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes.” The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company’s products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

For more information, please click here

Contacts:
Redwood Consultants, LLC
Jens Dalsgaard, 415-884-0348
or
The Investor Relations Group
212-825-3210
Investor Relations:
Michael Crawford

or
Brett Foley

or
Emily Hanan

or
Media Relations:
Ambrose Aban

or
Susan Morgenbesser